COVID-19 Developed During Systemic Steroid Therapy for Vogt-Koyanagi-Harada Disease: A Case Report

References

• World Health Organization (WHO). COVID-19 weekly epidemiological update. Geneva: WHO; 2023. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19—15-february-2023. Accessed Feburuary 15, 2023.
   Google Scholar
• Agarwal AK, Sudharshan S, Mahendradas P, et al. Impact of COVID-19 pandemic on uveitis patients receiving immunomodulatory and biological therapies (COPE STUDY). Br J Ophthalmol. 2022;106(1):97–101. doi:10.1136/bjophthalmol-2020-317417.
   PubMed Web of Science ®Google Scholar
• Ziadé N, El Kibbi L, Hmamouchi I, et al. Impact of the COVID-19 pandemic on patients with chronic rheumatic diseases: a study in 15 Arab countries. Int J Rheum Dis. 2020;23(11):1550–1557. doi:10.1111/1756-185X.13960.
   PubMed Web of Science ®Google Scholar
• Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA. 2020;323(13):1239–1242. doi:10.1001/jama.2020.2648.
   PubMed Web of Science ®Google Scholar
• Kim JS, Jun Lee Y, Yang JW, et al. Immunopathogenesis and treatment of cytokine storm in COVID-19. Theranostics. 2021;11(1):316–329. doi:10.7150/thno.49713.
   PubMed Web of Science ®Google Scholar
• Sonoda KH, Hasegawa E, Namba K, Okada AA, Ohguro N, Goto H. Epidemiology of uveitis in Japan: a 2016 retrospective nationwide survey. Jpn J Ophthalmol. 2021;65(2):184–190. doi:10.1007/s10384-020-00809-1.
   PubMed Web of Science ®Google Scholar
• Saraceno JJF, Souza GM, Dos Santos Finamor LP, Nascimento HM, Belfort R. Vogt-Koyanagi-Harada Syndrome following COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccine. Int J Retina Vitreous. 2021;7(1):49. doi:10.1186/s40942-021-00319-3.
   PubMedGoogle Scholar
• Mikuls TR, Johnson SR, Fraenkel L, et al. American college of rheumatology guidance for the management of rheumatic disease in adult patients during the COVID-19 pandemic: version 1. Arthritis Rheumatol. 2020;72(8):1241–1251. doi:10.1002/art.41301.
   Google Scholar
• Belsky JA, Tullius BP, Lamb MG, Sayegh R, Stanek JR, Auletta JJ. COVID-19 in immunocompromised patients: a systematic review of cancer, hematopoietic cell and solid organ transplant patients. J Infect. 2021;82(3):329–338. doi:10.1016/j.jinf.2021.01.022.
   PubMed Web of Science ®Google Scholar
• Roongta R, Ghosh A. Managing rheumatoid arthritis during COVID-19. Clin Rheumatol. 2020;39(11):3237–3244. doi:10.1007/s10067-020-05358-z.
   PubMed Web of Science ®Google Scholar
• Sanjay S, Mutalik D, Gowda S, Mahendradas P, Kawali A, Shetty R. Post coronavirus disease (COVID-19) reactivation of a quiescent unilateral anterior uveitis. SN Compr Clin Med. 2021;3(9):1843–1847. doi:10.1007/s42399-021-00985-2.
   PubMedGoogle Scholar
• Du L, Kijlstra A, Yang P. Vogt-Koyanagi-Harada disease: novel insights into pathophysiology, diagnosis and treatment. Prog Retin Eye Res. 2016;52:84–111. doi:10.1016/j.preteyeres.2016.02.002.
   PubMed Web of Science ®Google Scholar
• Nakayama M, Okada AA, Hayashi I, Ando Y, Watanabe T, Keino H. A COVID-19 risk reduction strategy for the treatment of acute Vogt-Koyanagi-Harada disease utilizing the antiviral potential of cyclosporine. Ocul Immunol Inflamm. 2023;31(2):462–467. doi:10.1080/09273948.2022.2028293.
   PubMedGoogle Scholar
• Singh AK, Majumdar S, Singh R, Misra A. Role of corticosteroid in the management of COVID-19: a systemic review and a Clinician’s perspective. Diabetes Metab Syndr. 2020;14(5):971–978. doi:10.1016/j.dsx.2020.06.054.
   PubMed Web of Science ®Google Scholar
• RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384:693–704
   PubMed Web of Science ®Google Scholar
• Neurath MF. COVID-19 and immunomodulation in IBD. Gut. 2020;69(7):1335–1342. doi:10.1136/gutjnl-2020-321269.
   PubMed Web of Science ®Google Scholar
• Catanzaro M, Fagiani F, Racchi M, Corsini E, Govoni S, Lanni C. Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2. Signal Transduct Target Ther. 2020;5(1):84. doi:10.1038/s41392-020-0191-1.
   PubMed Web of Science ®Google Scholar
• van Paassen J, Vos JS, Hoekstra EM, et al. Corticosteroid use in COVID-19 patients: a systematic review and meta-analysis on clinical outcomes. Crit Care. 2020;24(1):696. doi:10.1186/s13054-020-03400-9.
   PubMed Web of Science ®Google Scholar
• Singh AK, Jena A, Kumar-M P, Sharma V, Sebastian S. Risk and outcomes of coronavirus disease in patients with inflammatory bowel disease: a systematic review and meta-analysis. United European Gastroenterol J. 2021;9(2):159–176. doi:10.1177/2050640620972602.
   PubMed Web of Science ®Google Scholar
• Xia Y, Sun S, Shi Y, Wang H, Zhao R, Sheng J. SARS-CoV-2 viral load in sputum correlates with risk of COVID-19 progression. Crit Care. 2020;24(1):170. doi:10.1186/s13054-020-02893-8.
   PubMed Web of Science ®Google Scholar
• Hu Z, Song C, Xu C, et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. Sci China Life Sci. 2020;63(5):706–711. doi:10.1007/s11427-020-1661-4.
   PubMed Web of Science ®Google Scholar
• Liu Y, Sawalha AH, Lu Q. COVID-19 and autoimmune diseases. Curr Opin Rheumatol. 2021;33(2):155–162. doi:10.1097/BOR.0000000000000776.
   PubMed Web of Science ®Google Scholar
• Lighter J, Phillips M, Hochman S, et al. Obesity in patients younger than 60 years is a risk factor for COVID-19 hospital admission. Clin Infect Dis. 2020;71(15):896–897. doi:10.1093/cid/ciaa415.
   PubMed Web of Science ®Google Scholar
• Green WD, Beck MA. Obesity impairs the adaptive immune response to influenza virus. Ann Am Thorac Soc. 2017;14(Supplement_5):406–409. doi:10.1513/AnnalsATS.201706-447AW.
   PubMedGoogle Scholar
• Llamas-Velasco M, Ovejero-Merino E, Salgado-Boquete L, et al. Obesity — a risk factor for psoriasis and COVID-19. Actas Dermosifiliogr. 2021;112(6):489–494. doi:10.1016/j.adengl.2021.03.013.
   PubMed Web of Science ®Google Scholar
• Rubin DT, Feuerstein JD, Wang AY, Cohen RD. AGA clinical practice update on management of inflammatory bowel disease during the COVID-19 pandemic: expert commentary. Gastroenterology. 2020;159(1):350–357. doi:10.1053/j.gastro.2020.04.012.
   PubMed Web of Science ®Google Scholar